AiVita Biomedical
PrivateLast Round
Series B
Extension
Dec 29, 2020
Total Funding Raised
$60.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
AiVita Biomedical is a biotechnology company that develops personalized vaccines for infectious diseases and cancer treatment, as well as innovative vaccine kits for pathogen readiness.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Fashion & Beauty
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AiVita Biomedical Comparables
Compare AiVita Biomedical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Amphera B.V. | 73% | |
| Diakonos Oncology | 72% | |
| CellResearch Corporation | 72% |
AiVita Biomedical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Dec 29, 2020 | ||||
| Series B | Feb 25, 2020 | ||||
| Grant | Jul 17, 2018 | ||||
| Series B | Jun 11, 2018 | ||||
| Grant | Sep 29, 2016 | ||||
Grant | Jul 7, 2016 |
Key People
Founding team and executive leadership
AiVita Biomedical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Eye Institute (NIH) | Grant |
| NIH RADx | Grant |
| California Technology Ventures | Series A |
| California Institute for Regenerative Medicine | Grant |
| National Eye Institute | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 84% MoM, reaching 3K.
- Dec 29, 2020
Raised $25M in a Series B Extension round.
Recent news
Latest coverage and updates
- hiresAug 18, 2026
AIVITA Biomedical, Inc. hired Larry Brilliant as board of directors on Aug 18th '26.
- recognized_asAug 13, 2026
Hans S. Keirstead at AIVITA Biomedical, Inc. recognized as 2026 Prix Galien USA nominee in the "Best Startup" category at Prix Galien USA Awards on Jul 1st '26.
- receives_awardAug 13, 2026
AIVITA Biomedical, Inc. will receive award 2026 Prix Galien USA award at Prix Galien USA Awards Ceremony on Oct 29th '26.
AiVita Biomedical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about AiVita Biomedical's valuation, stock price, and market status.
Is AiVita Biomedical a public or private company?
AiVita Biomedical is a private company.
What is the current stock price of AiVita Biomedical?
AiVita Biomedical is a private company with no public stock price. No recent secondary market data is available.
How much is AiVita Biomedical worth (valuation)?
Valuation information for AiVita Biomedical is not publicly available.
Can I buy AiVita Biomedical stock?
AiVita Biomedical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was AiVita Biomedical's last funding round?
AiVita Biomedical's most recent funding round was Series B Extension on December 29, 2020.
Who are the main investors in AiVita Biomedical?
Key investors in AiVita Biomedical include California Technology Ventures.
Will AiVita Biomedical IPO soon?
No public IPO plans have been announced for AiVita Biomedical.
How can I track AiVita Biomedical secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AiVita Biomedical's secondary market activity and sign up for updates.